{"entity":{"id":"gecacitinib","kind":"drug","name":"Gecacitinib","aka":[],"tldr":"Gecacitinib is an oral kinase inhibitor from Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in registered phase 2 trials for cervical cancer.","summary":"Gecacitinib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, in cervical cancer. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Gecacitinib","url":"https://clinicaltrials.gov/search?intr=Gecacitinib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["zelgen"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07080216"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral kinase inhibitor","mechanism":"A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/gecacitinib/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"company":[{"id":"zelgen","kind":"company","name":"Suzhou Zelgen Biopharmaceuticals","route":"/companies/zelgen/"}],"trial":[{"id":"nct06903377","kind":"trial","name":"Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer","route":"/trials/nct06903377/"},{"id":"nct07080216","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer","route":"/trials/nct07080216/"},{"id":"nct06883526","kind":"trial","name":"Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma","route":"/trials/nct06883526/"}]}}